Cdc42GAP缺乏有助于阿尔茨海默病的表型
Mengjuan Zhu1, Bin Xiao1, Tao Xue1
1Guangdong Provincial Key Laboratory of Functional Proteomics, Key Laboratory of Mental Health of the Ministry of Education, School of Basic Medical Sciences, Department of Otorhinolaryngology-Head and Neck Surgery of the Third Affiliated Hospital, Southern Medical University, Guangzhou 510515, China.
Brain : a journal of neurology
|May 31, 2023
概括
Cdc42GAP缺乏通过增加Cdc42活性来加速阿尔茨海默病 (AD) 的进展,从而导致认知缺陷和AD病理. 准Cdc42可能为AD提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样质斑块,神经纤维状结和突触损失.
- Cdc42,一个小的GTPase,调节突触可塑性,其失调与神经系统疾病有关.
- 虽然Cdc42GAP调节了Cdc42的活性,但它在AD病变发生过程中的作用仍然很大程度上未被探索.
研究的目的:
- 为了研究Cdc42GAP在阿尔茨海默病类似表型的进展中的作用.
- 阐明将Cdc42GAP缺乏与AD病理联系起来的分子机制.
主要方法:
- 使用了异合体Cdc42GAP小鼠模型,表现出Cdc42-GTPase活性升高.
- 评估认知行为,神经元衰老,突触完整性和AD特异性病理 (陶酸化,Aβ水平).
- 进行了定量蛋白质组分析和体外神经元培养实验.
- 检查了来自AD患者和健康对照组的人类皮质样本.
主要成果:
- 在小鼠中,Cdc42GAP缺乏导致认知功能受损,神经元衰老,突触损失, fosforylation和Aβ积累增加.
- 这些损伤与年龄有关,并且与通过Cdc42-PAK1-cofilin信号传递激活GSK-3β有关.
- 过度表达主导阴性Cdc42改善了Cdc42GAP缺乏的小鼠神经元中的突触损失和tau过酸化.
- 在人类AD皮质样本中观察到Cdc42信号,Aβ水平和GSK-3β活性升高.
结论:
- Cdc42GAP在调节AD类表型方面发挥着关键作用,包括认知衰退,突触损失,病理和粉样蛋白负担.
- 缺乏Cdc42GAP会加剧AD的进展,可能是通过GSK-3β激活,这表明Cdc42是治疗点.
- 这项研究提供了第一个证据,将Cdc42信号与阿尔茨海默病的进展联系起来.
相关概念视频
03:14Notch Signaling Pathway
4.3K
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.3K
01:26Alzheimer's Disease: Overview
539
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
539